DekaBank Deutsche Girozentrale Acquires 86 Shares of Charles River Laboratories International, Inc. $CRL

DekaBank Deutsche Girozentrale increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 1.2% during the 2nd quarter, HoldingsChannel reports. The firm owned 7,142 shares of the medical research company’s stock after purchasing an additional 86 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Charles River Laboratories International were worth $1,072,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Chicago Partners Investment Group LLC acquired a new stake in Charles River Laboratories International in the 2nd quarter valued at approximately $315,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Charles River Laboratories International in the 2nd quarter valued at approximately $1,897,000. Bayforest Capital Ltd acquired a new stake in Charles River Laboratories International in the 2nd quarter valued at approximately $63,000. Boston Trust Walden Corp raised its position in Charles River Laboratories International by 9.6% in the 2nd quarter. Boston Trust Walden Corp now owns 225,191 shares of the medical research company’s stock valued at $34,168,000 after buying an additional 19,789 shares during the last quarter. Finally, Sequoia Financial Advisors LLC raised its position in Charles River Laboratories International by 95.6% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 3,432 shares of the medical research company’s stock valued at $521,000 after buying an additional 1,677 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Up 3.4%

NYSE:CRL opened at $197.52 on Monday. The firm has a market capitalization of $9.72 billion, a price-to-earnings ratio of -148.51, a price-to-earnings-growth ratio of 5.28 and a beta of 1.50. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $230.02. The stock’s 50 day moving average price is $164.43 and its two-hundred day moving average price is $150.38. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.50 by $0.62. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. During the same period in the previous year, the company posted $2.80 EPS. The firm’s revenue for the quarter was up .6% compared to the same quarter last year. Equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 800 shares of Charles River Laboratories International stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the completion of the transaction, the executive vice president directly owned 24,116 shares in the company, valued at approximately $3,800,681.60. The trade was a 3.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Evercore ISI lifted their target price on Charles River Laboratories International from $190.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, October 3rd. Barclays raised Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $165.00 to $195.00 in a research report on Thursday, October 2nd. Citigroup raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $150.00 to $200.00 in a research report on Wednesday, July 9th. Jefferies Financial Group raised Charles River Laboratories International from a “hold” rating to a “buy” rating and boosted their price target for the stock from $142.00 to $195.00 in a research report on Tuesday, September 9th. Finally, Mizuho boosted their price target on Charles River Laboratories International from $155.00 to $174.00 and gave the stock a “neutral” rating in a research report on Friday, October 17th. Eight analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $181.29.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).